重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 10 月 28 日 （二） 股东大会召开的地点：深圳市南山区高新中一道与科技中一路交汇处创 益科技大厦 B 栋 19 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 证券代码：688136 证券简称：科兴制药 公告编号：2024-071 科兴生物制药股份有限公司 2024 年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 1、出席会议的股东和代理人人数 | 107 | | --- | --- | | 普通股股东人数 | 107 | | 2、出席会议的股东所持有的表决权数量 | 136,573,133 | | 普通股股东所持有表决权数量 | 136,573,133 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 69.2147 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 6 ...

Investment Rating - The investment rating for Kexing Pharmaceutical is "Recommended (Maintain)" [2][7] Core Views - The company's revenue for the first three quarters of 2024 reached 1.038 billion yuan, an increase of 7.15%, while the net profit attributable to shareholders was 17 million yuan, up 131.63% [5][6] - The company is focusing on the overseas market, with significant growth in sales of its biological drugs, particularly the albumin paclitaxel, which has received EU approval and is experiencing increasing sales orders [6][7] - The reduction in sales and R&D expense ratios has contributed to the continuous recovery of the company's profitability [6][7] Summary by Sections Financial Performance - For the first three quarters of 2024, Kexing Pharmaceutical achieved a revenue of 1.038 billion yuan, a year-on-year increase of 7.15%, and a net profit of 17 million yuan, reflecting a growth of 131.63% [5][6] - The company’s sales expense ratio decreased by 12.23 percentage points to 43.15%, while the R&D expense ratio fell by 6.45 percentage points to 10.93% [6] Market Expansion - The company’s overseas sales revenue reached 149 million yuan, a year-on-year increase of 47%, with domestic cooperative product revenue growing by 80% compared to the same period last year [6] - Kexing has signed contracts for 13 new products with over 40 countries and is actively submitting registration applications [6][7] Future Outlook - Revenue forecasts for 2024, 2025, and 2026 are projected at 1.568 billion yuan, 2.071 billion yuan, and 2.692 billion yuan, respectively, with net profit estimates of 35 million yuan, 118 million yuan, and 257 million yuan [7] - The company is advancing multiple projects in clinical trials, including two in Phase III, which are expected to support future growth [7]

科兴生物制药股份有限公司（以下简称"公司"）第二届监事会第十七次会 议于 2024 年 10 月 24 日以现场表决方式召开。会议通知已于 2024 年 10 月 21 日 发出。本次会议应出席监事 3 人，实际出席监事 3 人。 证券代码：688136 证券简称：科兴制药 公告编号：2024-069 科兴生物制药股份有限公司 第二届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 （二）审议通过《关于重新审议关联交易协议的议案》 公司监事会认为：公司全资子公司深圳科兴药业有限公司向正中产业控股集 团有限公司租赁房产，是根据实际业务发展需要而发生的。本次重新审议关联交 易协议符合《上海证券交易所科创板股票上市规则》和《公司章程》的规定，交 易定价公平、合理，不会对公司及公司财务状况、经营成果产生不利影响，不会 损害公司及全体股东特别是中小股东利益，不会影响公司的独立性，也不会对公 司持续经营产生不利影响。 表决结果：3 票同意，0 票反对，0 票弃权。 会议由监事会主席江海 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-070 关于重新审议关联交易协议的公告 科兴生物制药股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 是否需要提交股东大会审议：否。 公司全资子公司深圳科兴药业有限公司向正中产业控股集团有限公司租 赁房产作为厂房及配套设施使用，租赁面积为 15,954.9 平方米，租金为每月 25 元/平方米，三年租金总额为 1,435.94 万元，重新审议关联交易协议前后租赁面 积及租金均未发生变化。 对上市公司的影响：公司与关联方的日常关联交易是为了满足公司日常 业务发展需要，为正常的持续性合作。公司本次重新审议关联交易协议符合《上 海证券交易所科创板股票上市规则》和《公司章程》的规定，交易定价公平、合 理，不会对公司及公司财务状况、经营成果产生不利影响，不会损害公司及全体 股东特别是中小股东利益，不会影响公司的独立性，也不会对公司持续经营产生 不利影响。 一、关联交易概述 公司全资子公司深圳科兴药业有限公司（以下简称"深圳科兴药业"）向正 中产 ...

Revenue and Profit Performance - Revenue for the first three quarters of 2024 reached RMB 1.038 billion, a year-on-year increase of 7.15%[2] - Overseas revenue grew by 47.16% year-on-year, surpassing the total amount for the full year of 2023[7] - Domestic sales increased year-on-year, driven by the company's focus on terminal markets and deep cultivation of niche markets[7] - Net profit attributable to shareholders for the first three quarters was RMB 17.18 million, with a significant year-on-year increase[7] - Overseas revenue reached 1.49 billion yuan, a year-on-year increase of 47.16%, while domestic revenue was 8.89 billion yuan, up 2.47% year-on-year, with total revenue of 10.38 billion yuan, a 7.15% increase[8] - Net profit attributable to parent company shareholders was RMB 17.18 million, compared to a loss of RMB 54.31 million in the same period last year[19] - Net profit attributable to the parent company increased from 125,451,529.17 RMB to 142,629,780.58 RMB, a growth of approximately 13.7%[15] - Total comprehensive income was RMB 14.11 million, compared to a loss of RMB 58.13 million in the same period last year[19] R&D Investment and Expenses - R&D investment for the first three quarters was RMB 135.39 million, a year-on-year decrease of 52.73%[3] - R&D investment as a percentage of revenue decreased by 16.52 percentage points to 13.04%[3] - R&D expenses decreased to RMB 113.45 million, down 32.6% year-over-year from RMB 168.37 million[18] Cash Flow and Financial Position - Operating cash flow for the first three quarters was RMB 53.27 million, primarily due to reduced operating expenses[7] - Net cash flow from operating activities was RMB 53.27 million, a significant improvement from a net outflow of RMB 74.49 million in the same period last year[21] - Cash received from selling goods and providing services was RMB 864.23 million, a decrease of 3.2% year-over-year[21] - Cash paid for employee compensation decreased to RMB 172.34 million, down 13.0% from RMB 198.15 million in the same period last year[21] - Cash received from investment activities increased to RMB 1.49 billion, up 15.5% from RMB 1.29 billion in the same period last year[21] - Cash paid for construction of fixed assets and intangible assets decreased to RMB 67.24 million, down 61.3% from RMB 173.78 million in the same period last year[21] - Investment cash outflow totaled 1,725,561,951.91, with a net cash flow from investment activities of -234,917,275.06[22] - Cash received from financing activities amounted to 436,755,263.90, with a net cash flow from financing activities of -74,485,021.37[22] - Cash and cash equivalents at the end of the period were 304,529,264.60, a decrease from the beginning balance of 559,930,585.75[22] - Cash paid for investment-related activities was 13,320,050.00[22] - Cash received from borrowing was 436,755,263.90[22] - Cash paid for debt repayment was 437,332,505.83[22] - Cash paid for dividends, profits, or interest was 33,494,795.65[22] - Cash paid for other financing-related activities was 40,412,983.79[22] - The impact of exchange rate changes on cash and cash equivalents was 731,760.74[22] - The net increase in cash and cash equivalents was -255,401,321.15[22] Asset and Liability Changes - Total assets at the end of the reporting period were RMB 3.031 billion, a slight decrease of 1.02% compared to the end of the previous year[3] - Equity attributable to shareholders at the end of the reporting period was RMB 1.626 billion, a slight decrease of 0.68% compared to the end of the previous year[3] - Total assets decreased slightly from 3,031,093,090.30 RMB to 3,000,193,448.63 RMB[15] - Accounts receivable increased from 274,522,885.16 RMB to 406,029,832.16 RMB, a growth of approximately 47.9%[13] - Inventory decreased from 191,364,918.26 RMB to 141,623,802.19 RMB, a reduction of approximately 26%[13] - Total current liabilities increased from 669,994,863.31 RMB to 762,936,045.47 RMB, a growth of approximately 13.9%[14] - Long-term liabilities decreased from 730,303,133.29 RMB to 616,901,503.97 RMB, a reduction of approximately 15.5%[14] International Market Expansion - The company achieved a major breakthrough in the EU market with the approval and first shipment of albumin-bound paclitaxel in July and August 2024, respectively, leading to increased sales orders[8] - The self-built albumin-bound paclitaxel production line has been registered with the EU, which is expected to improve sales gross margins[8] - A new subsidiary was established in Germany to boost sales of albumin-bound paclitaxel in the EU and the UK[8] - Self-produced products such as EPO, GC, and Chang Lekang expanded into more international markets, with overseas sales gross margin increasing by 6.25% year-on-year in the first three quarters of 2024[8] - The company accelerated sales and registration of introduced products in emerging markets, including the first shipment of infliximab to Peru and GMP inspections for adalimumab in the Philippines and liraglutide in Colombia[9] Shareholder and Equity Information - The top shareholder, Shenzhen Keyi Pharmaceutical Holding Co., Ltd., holds 66.15% of the company's shares[10] - The company's top 10 shareholders include institutional investors such as CITIC Securities and China Merchants Fund Management, with no shares pledged or frozen[10] - The company's total number of ordinary shareholders at the end of the reporting period was 8,947[10] Earnings Per Share and Financial Ratios - Basic earnings per share for the first three quarters were RMB 0.09[2] - Basic earnings per share were RMB 0.09, compared to a loss per share of RMB 0.27 in the same period last year[19]

科兴生物制药股份有限公司 2024 年第三次临时股东大会会议资料 证券代码：688136 证券简称：科兴制药 科兴生物制药股份有限公司 2024 年第三次临时股东大会 会议资料 二〇二四年十月 科兴生物制药股份有限公司 2024 年第三次临时股东大会会议资料 科兴生物制药股份有限公司 2024 年第三次临时股东大会会议资料目录 | 2024 | 年第三次临时股东大会会议须知 | 1 | | --- | --- | --- | | 2024 | 年第三次临时股东大会会议议程 | 3 | | 2024 | 年第三次临时股东大会会议议案 | 4 | | | 议案一 关于变更会计师事务所的议案 | 4 | 科兴生物制药股份有限公司 2024 年第三次临时股东大会会议资料 2024 年第三次临时股东大会会议须知 为了维护科兴生物制药股份有限公司（以下简称"公司"或"本公司"）股 东的合法权益，确保股东大会的正常秩序、议事效率，根据有关法律法规及《科 兴生物制药股份有限公司章程》（以下简称"《公司章程》"）、《科兴生物制药股份 有限公司股东大会议事规则》（以下简称"《股东大会议事规则》"）的相关要求， 特制定如下会议须知 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-068 科兴生物制药股份有限公司 自愿披露关于注射用紫杉醇（白蛋白结合型）获得英国上市许可 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）合作伙伴浙江海昶生物医 药技术有限公司于近日收到英国药品和健康产品管理局（以下简称"英国药监局"） 核准签发的关于公司引进产品注射用紫杉醇（白蛋白结合型）（Apexelsin®，以 下简称"白蛋白紫杉醇"）的上市许可。 注射用紫杉醇（白蛋白结合型）剂型具备临床用药优势，相对普通紫杉醇注 射液和紫杉醇脂质体，安全性和患者依从性有所提升，临床认可度较高，在肿瘤 治疗领域具有不可或缺的临床价值。 二、对公司的影响 公司积极推动在欧洲市场的营销渠道布局和拓展，公司引进的白蛋白紫杉醇 已在欧盟获得上市许可。本次白蛋白紫杉醇在英国获批上市，有利于公司进一步 加快推进海外市场的拓展，提高公司的市场竞争力，未来将对公司经营产生积极 影响。 三、风险提示 由于医药产品的行业特点，药品的具体 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-066 科兴生物制药股份有限公司 关于变更会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2011 年经北京市财政局批准转制为特殊普通合伙，2012 年更名为致同会计师事 务所(特殊普通合伙)。） （3）组织形式：特殊普通合伙企业 重要内容提示： 拟聘任的会计师事务所名称：致同会计师事务所（特殊普通合伙）（以下 简称"致同"） 原聘任的会计师事务所名称：大华会计师事务所（特殊普通合伙）（以下 简称"大华"） 根据《国有企业、上市公司选聘会计师事务所管理办法》相关规定，结 合公司业务发展、审计工作需求等情况，为保证公司审计工作的独立性、客观性， 经履行招标程序并根据评标结果，公司拟变更会计师事务所，聘任致同为公司 2024 年度财务报告和内部控制审计机构。公司已就变更会计师事务所相关事项 与前任会计师事务所大华进行了沟通，大华已知悉本事项且未提出异议。 本事项尚需股东大会审议。 科兴生物制药股份有限公司（简称"公司"）于 2024 年 10 ...

重要内容提示： 证券代码：688136 证券简称：科兴制药 公告编号：2024-067 科兴生物制药股份有限公司 关于召开 2024 年第三次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年第三次临时股东大会 召开日期时间：2024 年 10 月 28 日 14 点 00 分 召开地点：深圳市南山区高新中一道与科技中一路交汇处创益科技大厦 B 栋 19 楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 10 月 28 日 至 2024 年 10 月 28 日 股东大会召开日期：2024年10月28日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统 ...

Investment Rating - The report assigns a "Buy" rating for the company, with a current stock price of 14.10 yuan and a projected PE ratio of 68.8/26.9/12.3 for the years 2024-2026 [1][3]. Core Insights - The company is positioned to accelerate its overseas business, leveraging over 20 years of marketing experience to build a robust global network. The dual-driven model of "innovation + overseas commercialization" is expected to enhance the export of high-quality domestic biopharmaceuticals [3][11]. - The impact of regional centralized procurement is gradually diminishing, leading to a recovery in sales for core products. The company anticipates steady growth in revenue and profitability in the coming years [2][21]. - The company has successfully introduced 13 advantageous products, with plans to introduce over 15-20 more by 2025, enhancing its product matrix across various therapeutic areas [4][11]. Summary by Sections Company Overview - The company focuses on the research, production, and sales of recombinant protein drugs and micro-ecological preparations, targeting key medical fields such as antiviral, oncology, and immune system diseases [11][13]. Financial Performance - In 2023, the company reported revenue of 12.59 billion yuan, a decline of 4.32% year-on-year. However, in the first half of 2024, revenue increased by 17.09% to 7.60 billion yuan, with a net profit of 21.53 million yuan, marking a significant turnaround [21][22]. Product Portfolio - The company has a diverse product line, including six proprietary products and several introduced products in oncology and immune therapy. Key products include Erythropoietin (依普定) and Interferon α1b (赛若金), which are leading in their respective markets [13][14][27]. Market Expansion - The company has established a comprehensive marketing system, covering approximately 22,700 medical institutions and pharmacies, with a focus on expanding its overseas market presence [20][21]. Future Outlook - The company projects a net profit of 0.41 billion yuan in 2024, increasing to 2.28 billion yuan by 2026, with a corresponding EPS growth from 0.20 yuan to 1.15 yuan [3][5].